CXCL9 and breast carcinoma: For example, the DYN + subgroup has higher expression of CXCL9 which was demonstrated to associate with higher pCR rate in breast cancer patients receiving NAC in previous study [49]; HLA-DPB1 was up-regulated in DYN + subgroup and was also assocaited with more tumor infiltrating lymphcytes and thereby better prognosis [50].